|Bid||14.10 x 1800|
|Ask||15.30 x 1200|
|Day's Range||14.13 - 14.98|
|52 Week Range||8.88 - 26.67|
|Beta (5Y Monthly)||1.68|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 10, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||33.25|
\- Results from global KALM-2 pivotal Phase 3 trial of KORSUVA™ Injection in hemodialysis patients with pruritus to be presented – \- NDA submission for KORSUVA Injection on track for fourth quarter 2020 -STAMFORD, Conn., Oct. 21, 2020 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, today announced that results from its KALM-2 pivotal Phase 3 trial of KORSUVA™ (CR845/difelikefalin) Injection in hemodialysis patients with moderate-to-severe chronic kidney disease-associated pruritus (CKD-aP) will be presented at the American Society of Nephrology (ASN) Kidney Week 2020 annual meeting, which is being held virtually from October 22-25, 2020.Details for the oral presentation are as follows:Title: Efficacy and Safety of Difelikefalin for Moderate-to-Severe CKD-Associated Pruritus: A Global Phase 3 Study in Hemodialysis Patients (KALM-2) Abstract Number: FR-OR24 Date and Time: Friday, October 23, 5 to 7 p.m. ET Presenter: Thomas D. Wooldridge, M.D., Nephrology and Hypertension Associates, Ltd., Tupelo, MSIn April 2020, the Company announced positive top-line results from KALM-2. The trial met the primary endpoint, with a statistically significant proportion of patients on KORSUVA Injection achieving a three-point or greater improvement from baseline in the weekly mean Worst Itching Intensity Numeric Rating Scale (NRS) versus placebo (p=0.02) at week 12. The trial also met the key secondary endpoint, with a statistically significant proportion of patients on KORSUVA Injection achieving a four-point or greater improvement from baseline in the weekly mean Worst Itching Intensity NRS versus placebo (p=0.01) at week 12. KORSUVA Injection was generally well-tolerated through 12 weeks of treatment with a safety profile consistent with prior clinical trials.The Company remains on track to submit a New Drug Application for KORSUVA Injection to the U.S. Food and Drug Administration in the fourth quarter of 2020.About Cara TherapeuticsCara Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, or KORs. Cara is developing a novel and proprietary class of product candidates, led by KORSUVA™ (CR845/difelikefalin), a first-in-class KOR agonist that targets the body’s peripheral nervous system, as well as certain immune cells. In two Phase 3 trials, KORSUVA Injection has demonstrated statistically significant reductions in itch intensity and concomitant improvement in quality of life measures in hemodialysis patients with moderate-to-severe chronic kidney disease-associated pruritus (CKD-aP). Cara has successfully completed its Phase 2 trial of Oral KORSUVA for the treatment of pruritus in patients with CKD and is currently conducting Phase 2 trials of Oral KORSUVA in atopic dermatitis and primary biliary cholangitis patients with moderate-to-severe pruritus.The FDA has conditionally accepted KORSUVA™ as the trade name for difelikefalin injection. CR845/difelikefalin is an investigational drug product and its safety and efficacy have not been fully evaluated by any regulatory authority.Forward-looking StatementsStatements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Examples of these forward-looking statements include statements concerning the expected timing for the submission of the Company’s NDA for KORSUVA Injection for CKD-aP, the Company’s ability to commercialize KORSUVA Injection and the Company’s potential future growth and success. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Risks are described more fully in Cara Therapeutics’ filings with the Securities and Exchange Commission, including the “Risk Factors” section of the Company’s most recent Quarterly Report on Form 10-Q and its other documents subsequently filed with or furnished to the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Cara Therapeutics undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.INVESTOR CONTACT: Janhavi Mohite Stern Investor Relations, Inc. 212-362-1200 janhavi.mohite@SternIR.comMEDIA CONTACT: Annie Starr 6 Degrees 973-415-8838 firstname.lastname@example.org
Cara Therapeutics (NASDAQ: CARA) shares are trading higher on Tuesday after the company announced it has signed a U.S. license agreement with Vifor Pharma for IV Korsuva to treat dialysis patients with Pruritus.Cara will receive an upfront payment of $100 million in cash and an equity investment of $50 million.Cara Therapeutics Inc is an emerging biotechnology company involved in the development of novel therapeutics to treat human diseases associated with inflammation, pain, and pruritus. Cara's most advanced compound, CR845, aims to treat acute pain and pruritus. This patented compound has analgesic, anti-inflammatory, and antipruritic properties that can be used for multiple therapeutic applications.Cara Therapeutics shares traded up 6.75% to $14.87 on Tuesday. The stock has a 52-week high of $26.67 and a 52-week low of $8.88.See more from Benzinga * Options Trades For This Crazy Market: Get Benzinga Options to Follow High-Conviction Trade Ideas * Why Crown Holdings Stock Is Trading Higher Today * Why Uber's Stock Is Trading Higher Today(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
During Q2, Cara Therapeutics (NASDAQ: CARA) brought in sales totaling $5.63 million. However, earnings decreased 13.72%, resulting in a loss of $25.88 million. Cara Therapeutics collected $8.09 million in revenue during Q1, but reported earnings showed a $30.00 million loss.What Is ROCE? Return on Capital Employed is a measure of yearly pre-tax profit relative to capital employed by a business. Changes in earnings and sales indicate shifts in a company's ROCE. A higher ROCE is generally representative of successful growth of a company and is a sign of higher earnings per share in the future. A low or negative ROCE suggests the opposite. In Q2, Cara Therapeutics posted an ROCE of -0.18%.Keep in mind, while ROCE is a good measure of a company's recent performance, it is not a highly reliable predictor of a company's earnings or sales in the near future.View more earnings on CARAReturn on Capital Employed is an important measurement of efficiency and a useful tool when comparing companies that operate in the same industry. A relatively high ROCE indicates a company may be generating profits that can be reinvested into more capital, leading to higher returns and growing EPS for shareholders.In Cara Therapeutics's case, the ROCE ratio shows the amount of assets may not be helping the company achieve higher returns. Investors may take this into account before making any long-term financial decisions.Q2 Earnings Insight Cara Therapeutics reported Q2 earnings per share at $-0.54/share, which beat analyst predictions of $-0.67/share.See more from Benzinga * Options Trades For This Crazy Market: Get Benzinga Options to Follow High-Conviction Trade Ideas * 11 Healthcare Stocks Moving In Tuesday's Pre-Market Session(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.